Observational studyRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2026
Appropriateness of antibiotic selection at emergency department discharge and risk of 30-day adverse events in patients with acute exacerbation of COPD.
Observational study in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe antibiotic prescribing patterns in acute exacerbations of chronic obstructive pulmonary disease (AECOPD) managed in emergency departments (EDs), assess the appropriateness of antibiotic selection according to Spanish guideline recommendations, and analyse its association with 30-day clinical outcomes.
methodsAnalysis derived from the multicentre retrospective EPOC-URG CAM registry (19 EDs in the Community of Madrid, 2022-2024), which included episodes of AECOPD. Antibiotic appropriateness was defined a priori according to national guideline recommendations. The primary outcome was the occurrence of an adverse event within 30 days, defined as recurrence of the exacerbation, ED revisit, hospitalisation, or death. The primary analysis was restricted to patients discharged directly from the ED with oral antibiotic treatment. Relative risks (RRs) were estimated using Poisson regression.
resultsA total of 4,136 episodes were analysed (mean age 74.5 ± 11.1 years; 68.3% male; 45.8% with a Charlson index ≥3). In the ED, 2,626 patients (63.5%) received antibiotics, with levofloxacin being the most frequently prescribed agent both in the ED (32.6%) and at discharge (39.3%). Patients' clinical profiles were very similar regardless of the antibiotic class prescribed at discharge. Of the 1,736 (42%) patients discharged directly from the ED, 987 (56.9%) received antibiotic treatment, and the prescription was considered inappropriate in 158 (16.0%). The incidence of 30-day adverse events was higher among patients receiving inappropriate antibiotic treatment (20.9% vs 13.3%; p=0.019). In the multivariable analysis, appropriate antibiotic treatment was the only modifiable factor independently associated with a lower risk of an adverse event (adjusted RR 0.59; 95% CI 0.41-0.85; p=0.004), whereas previous exacerbations (adjusted RR 1.80; 95% CI 1.15-2.83; p=0.010) and moderate exacerbation (adjusted RR 1.52; 95% CI 1.10-2.11; p=0.012) were associated with a higher risk.
conclusionsAntibiotic prescribing for AECOPD managed in the ED was characterised by a predominance of fluoroquinolones and limited individualisation according to patients' clinical profiles. Among patients discharged directly from the ED, antibiotic selection in accordance with national recommendations was independently associated with a reduced risk of a 30-day adverse event.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.